Literature DB >> 31078566

The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins.

Katsuyuki Nakajima1, Yoshiharu Tokita2, Akira Tanaka3, Sadao Takahashi4.   

Abstract

A new concept to account for the process of postprandial remnant lipoprotein metabolism is proposed based on the characteristics of lipoprotein particles and their receptors. The characteristics of remnant lipoprotein (RLP) were investigated using an immuno-separation method. The majority of the postprandial lipoproteins increased after fat intake was shown to be VLDL remnants, not chylomicron (CM) remnants, based on the significantly high ratio of apoB100/apoB48 in the RLP and the high degree of similarity in the particle size of the apoB48 and apoB100 carrying lipoproteins, which fluctuate in parallel during a 6 h period after fat intake. The VLDL receptor was discovered as a receptor for TG-rich lipoprotein metabolism and is located in peripheral tissues such as skeletal muscle, adipose tissue, etc., but not in the liver. Postprandial VLDL particles are strongly bound and internalized into cells expressing the VLDL receptor. Ligands that bind to VLDL receptor, such as LPL and Lp(a), present in RLP. The presence of various specific ligands in VLDL remnants may enhance the capacity for binding to the VLDL receptor, which play the role primarily for energy delivery to the peripheral tissues, but is also a causal factor in atherogenic diseases when excessively and/or continuously remained in plasma.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adiponectin; ApoE; Chylomicron (CM) remnants; Fat load; Lipoprotein lipase (LPL); Low density lipoprotein (LDL) receptor; Lp(a); Metallothionein (I/II); PCSK9; Postprandial lipoproteins; Remnant lipoproteins (RLP); VLDL remnants; Very low density lipoprotein (VLDL) receptor

Mesh:

Substances:

Year:  2019        PMID: 31078566     DOI: 10.1016/j.cca.2019.05.004

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Metabolism of Triglyceride-Rich Lipoproteins.

Authors:  Jan Borén; Marja-Riitta Taskinen
Journal:  Handb Exp Pharmacol       Date:  2022

2.  Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects.

Authors:  María Molina-Vega; Daniel Castellano-Castillo; Lidia Sánchez-Alcoholado; Isaac Plaza-Andrade; Gabriel Perera-Martin; Amanda Cabrera-Mulero; Jose Carlos Fernández-García; Bruno Ramos-Molina; Fernando Cardona; Francisco J Tinahones
Journal:  Biomolecules       Date:  2020-05-11

Review 3.  Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).

Authors:  Jih-Kai Huang; Hsiang-Chun Lee
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

4.  Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis.

Authors:  Chunyang Wang; Wentai Pang; Xuechen Du; Jiani Zhai; Mengyuan Zhong; Ming Zhuang; Jiali An; Lujia Cao; Li Zhang; Wenke Zheng; Junhua Zhang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 5.  Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights.

Authors:  Hsiang-Chun Lee; Alexander Akhmedov; Chu-Huang Chen
Journal:  Front Cardiovasc Med       Date:  2022-10-04

Review 6.  The Pathogenic Role of Very Low Density Lipoprotein on Atrial Remodeling in the Metabolic Syndrome.

Authors:  Hsiang-Chun Lee; Yi-Hsiung Lin
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

7.  The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome.

Authors:  Hsiang-Chun Lee; Shyi-Jang Shin; Jih-Kai Huang; Ming-Yen Lin; Yu-Hsun Lin; Liang-Yin Ke; He-Jiun Jiang; Wei-Chung Tsai; Min-Fang Chao; Yi-Hsiung Lin
Journal:  Lipids Health Dis       Date:  2020-09-22       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.